Patents by Inventor James R. Prudent

James R. Prudent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200384122
    Abstract: Extracellular drug conjugates (EDCs) targeting CD38 are useful in the treatment of diseases such as cancer and immune disorders, including asthma.
    Type: Application
    Filed: March 25, 2020
    Publication date: December 10, 2020
    Inventor: James R. Prudent
  • Patent number: 10675352
    Abstract: Extracellular drug conjugates (EDCs) targeting CD38 are useful in the treatment of diseases such as cancer and immune disorders, including asthma.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: June 9, 2020
    Assignee: Centrose, LLC
    Inventor: James R. Prudent
  • Publication number: 20190248887
    Abstract: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.
    Type: Application
    Filed: November 15, 2018
    Publication date: August 15, 2019
    Inventors: James R. Prudent, Jon S. Thorson
  • Patent number: 10240189
    Abstract: Solid support assays using non-standard bases are described. A capture oligonucleotide comprising a molecular recognition sequence is attached to a solid support and hybridized with a target. In some instances, the molecular recognition sequence includes one or more non-standard bases and hybridizes to a complementary tagging sequence of the target oligonucleotide. In other instances, incorporation of a non-standard base (e.g., via PCR or ligation) is used in the assay.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: March 26, 2019
    Assignee: LUMINEX CORPORATION
    Inventors: Jennifer K. Grenier, David J. Marshall, James R. Prudent, Craig S. Richmond, Eric B. Roesch, Christopher W. Scherrer, Christopher B. Sherrill, Jerod L. Ptacin
  • Publication number: 20190008983
    Abstract: Extracellular drug conjugates targeting nucleotide-metabolizing (ecto)-enzymes and the Na,K-ATPase and their use as therapeutics.
    Type: Application
    Filed: July 29, 2016
    Publication date: January 10, 2019
    Inventor: James R. Prudent
  • Patent number: 9611509
    Abstract: Assays using non-natural bases are described. In one embodiment, the method involves contacting a sample suspected of containing the target nucleic acid with a polymerase and first and second primers; amplifying the target nucleic acid by PCR using the first and second primers to generate an amplification product having a double-stranded region and a single-stranded region that comprises the non-natural base; contacting the sample with a reporter comprising a label and a non-natural base that is complementary to the non-natural base of the single-stranded region; annealing at least a portion of the reporter to the single-stranded region of the amplification product; and correlating a signal of the label with the presence of the target nucleic acid in the sample. The invention also provides corresponding kits for use in detecting target nucleic acids in a sample.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: April 4, 2017
    Assignee: LUMINEX CORPORATION
    Inventors: David J. Marshall, James R. Prudent, Christopher B. Sherrill, Gideon Shapiro, Jennifer K. Grenier, Craig S. Richmond, Simona Jurczyk, Jerod L. Ptacin
  • Publication number: 20170049908
    Abstract: Extracellular drug conjugates (EDCs) targeting an extracellular protein or portion thereof (e.g., CD38) and comprising a non-cleavable linker including one or two nitrogen heteroatoms are useful in the treatment of diseases such as cancer and immune disorders, including asthma.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 23, 2017
    Inventor: James R. Prudent
  • Publication number: 20160346403
    Abstract: Extracellular drug conjugates (EDCs) targeting CD38 are useful in the treatment of diseases such as cancer and immune disorders, including asthma.
    Type: Application
    Filed: February 17, 2015
    Publication date: December 1, 2016
    Inventor: James R. Prudent
  • Publication number: 20160279248
    Abstract: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.
    Type: Application
    Filed: June 7, 2016
    Publication date: September 29, 2016
    Inventors: Charles R. Hutchinson, James R. Prudent, Jon S. Thorson
  • Patent number: 9364554
    Abstract: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: June 14, 2016
    Assignee: Centrose LLC
    Inventors: Charles R. Hutchinson, James R. Prudent, Jon S. Thorson
  • Publication number: 20150132759
    Abstract: Solid support assays using non-standard bases are described. A capture oligonucleotide comprising a molecular recognition sequence is attached to a solid support and hybridized with a target. In some instances, the molecular recognition sequence includes one or more non-standard bases and hybridizes to a complementary tagging sequence of the target oligonucleotide. In other instances, incorporation of a non-standard base (e.g., via PCR or ligation) is used in the assay.
    Type: Application
    Filed: January 20, 2015
    Publication date: May 14, 2015
    Inventors: JENNIFER K. GRENIER, DAVID J. MARSHALL, JAMES R. PRUDENT, CRAIG S. RICHMOND, ERIC B. ROESCH, CHRISTOPHER W. SCHERRER, CHRISTOPHER B. SHERRILL, JEROD L. PTACIN
  • Patent number: 8969047
    Abstract: Solid support assays using non-standard bases are described. A capture oligonucleotide comprising a molecular recognition sequence is attached to a solid support and hybridized with a target. In some instances, the molecular recognition sequence includes one or more non-standard bases and hybridizes to a complementary tagging sequence of the target oligonucleotide. In other instances, incorporation of a non-standard base (e.g., via PCR or ligation) is used in the assay.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: March 3, 2015
    Assignee: Luminex Corporation
    Inventors: Jennifer K. Grenier, David J. Marshall, James R. Prudent, Craig S. Richmond, Eric B. Roesch, Christopher W. Scherrer, Christopher B. Sherrill, Jerod L. Ptacin
  • Publication number: 20140193436
    Abstract: Extracellular-targeted drug conjugates (EDC) in which a targeting moiety targeting a protein associated with the Na,K-ATPase is linked to a drug that interacts with the Na,K-ATPase through a linker a stable linker are useful in the treatment of disease and as tools for the evaluation of biological systems.
    Type: Application
    Filed: June 25, 2012
    Publication date: July 10, 2014
    Applicant: CENTROSE, LLC
    Inventor: James R. Prudent
  • Publication number: 20140079722
    Abstract: Antibodies targeting the dysadherin subunit of the human Na,K-ATPase signaling complex that are covalently linked via a stable linker to steroid drugs that bind the alpha subunit of that complex are useful in the treatment of cancer.
    Type: Application
    Filed: March 9, 2012
    Publication date: March 20, 2014
    Applicant: CENTROSE, LLC
    Inventor: James R. Prudent
  • Publication number: 20140057269
    Abstract: Assays using non-natural bases are described. In one embodiment, the method involves contacting a sample suspected of containing the target nucleic acid with a polymerase and first and second primers; amplifying the target nucleic acid by PCR using the first and second primers to generate an amplification product having a double-stranded region and a single-stranded region that comprises the non-natural base; contacting the sample with a reporter comprising a label and a non-natural base that is complementary to the non-natural base of the single-stranded region; annealing at least a portion of the reporter to the single-stranded region of the amplification product; and correlating a signal of the label with the presence of the target nucleic acid in the sample. The invention also provides corresponding kits for use in detecting target nucleic acids in a sample.
    Type: Application
    Filed: July 24, 2013
    Publication date: February 27, 2014
    Applicant: LUMINEX CORPORATION
    Inventors: David J. Marshall, James R. Prudent, Christopher B. Sherrill, Gideon Shapiro, Jennifer K. Grenier, Craig S. Richmond, Simona Jurczyk, Jerod L. Ptacin
  • Publication number: 20140024550
    Abstract: Solid support assays using non-standard bases are described. A capture oligonucleotide comprising a molecular recognition sequence is attached to a solid support and hybridized with a target. In some instances, the molecular recognition sequence includes one or more non-standard bases and hybridizes to a complementary tagging sequence of the target oligonucleotide. In other instances, incorporation of a non-standard base (e.g., via PCR or ligation) is used in the assay.
    Type: Application
    Filed: July 24, 2013
    Publication date: January 23, 2014
    Applicant: LUMINEX CORPORATION
    Inventors: Jennifer K. Grenier, David J. Marshall, James R. Prudent, Craig S. Richmond, Eric B. Roesch, Christopher W. Scherrer, Christopher B. Sherrill, Jerod L. Ptacin
  • Publication number: 20130336994
    Abstract: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.
    Type: Application
    Filed: May 20, 2013
    Publication date: December 19, 2013
    Applicant: CENTROSE, LLC
    Inventors: Charles R. Hutchinson, James R. Prudent, Jon S. Thorson
  • Patent number: 8519117
    Abstract: Assays using non-natural bases are described. In one embodiment, the method involves contacting a sample suspected of containing the target nucleic acid with a polymerase and first and second primers; amplifying the target nucleic acid by PCR using the first and second primers to generate an amplification product having a double-stranded region and a single-stranded region that comprises the non-natural base; contacting the sample with a reporter comprising a label and a non-natural base that is complementary to the non-natural base of the single-stranded region; annealing at least a portion of the reporter to the single-stranded region of the amplification product; and correlating a signal of the label with the presence of the target nucleic acid in the sample. The invention also provides corresponding kits for use in detecting target nucleic acids in a sample.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: August 27, 2013
    Assignee: Luminex Corporation
    Inventors: David J. Marshall, James R. Prudent, Christopher B. Sherrill, Gideon Shapiro, Jennifer K. Grenier, Craig S. Richmond, Simona Jurczyk, Jerod L. Ptacin
  • Patent number: 8518671
    Abstract: Solid support assays using non-standard bases are described. A capture oligonucleotide comprising a molecular recognition sequence is attached to a solid support and hybridized with a target. In some instances, the molecular recognition sequence includes one or more non-standard bases and hybridizes to a complementary tagging sequence of the target oligonucleotide. In other instances, incorporation of a non-standard base (e.g., via PCR or ligation) is used in the assay.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: August 27, 2013
    Assignee: Luminex Corporation
    Inventors: Jennifer K. Grenier, David J. Marshall, James R. Prudent, Craig S. Richmond, Eric B. Roesch, Christopher W. Scherrer, Christopher B. Sherrill, Jerod L. Ptacin
  • Patent number: 8470980
    Abstract: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: June 25, 2013
    Assignee: Centrose, LLC
    Inventors: James R. Prudent, Jon S. Thorson, Jill Hutchinson Bollettieri